<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82253">
  <stage>Registered</stage>
  <submitdate>2/09/2007</submitdate>
  <approvaldate>21/09/2007</approvaldate>
  <actrnumber>ACTRN12607000473460</actrnumber>
  <trial_identification>
    <studytitle>Study to evaluate the efficacy and safety of rosuvastatin in indian population who have diabetes with abnormal lipid levels (dyslipidemia)</studytitle>
    <scientifictitle>An Open-Label, Prospective, Non-Comparative Clinical Trial To Evaluate The Efficacy And Safety of Rosuvastatin In High Risk Indian Population With Diabetes and Dyslipidemia by evaluating the efficacy of Rosuvastatin in changing the Total Cholesterol, Low Density Lipoprotein, High Denisty Lipoprotein, and Triglycerides in Diabetic patients who have altered lipid levels (Dyslipidemia)</scientifictitle>
    <utrn />
    <trialacronym>RESIDD</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Dyslipidemia in patients with Diabetes Mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Rosuvastatin 10 mg once a day for first 6 weeks and if the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) guideline of Low Density Lipoprotein - Cholesterol (LDL-C) of less than 100 mg/dl is not achieved then the dose will be increased to 20 mg once a day for another 6 weeks</interventions>
    <comparator>Non Comparative</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Outcome will be measured by evaluating the blood samples of patients at Baseline, Week 6 and Week 12.
We will evaluate the mean change in the Total Cholesterol, Low Density Lipoprotein, High Denisty Lipoprotein, Triglycerides levels.</outcome>
      <timepoint>Baseline, Week 6 and Week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Change in high sensitive-C-Reactive Protein, apoprotein B, apoB/apoA1 ratio, apoprotein A1, lipoprotein a and glycosylated hemoglobine</outcome>
      <timepoint>Baseline, Week 6 and Week 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diabetes Type II defined by American Diabetes Association (ADA) criteria of fasting venous plasma glucose of = 126 mg/dl, 2 hour post prandial plasma glucose of = 200 mg/dl or already on treatment of diabetes. 
	Dyslipidemia defined by LDL Cholesterol more than 100 mg/dl or on prior statin therapy.
	Age of = 30 and = 70 years
	Informed consent by the patient.</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>	Failure to give informed consent 
	A history of hypersensitivity to statins
	Evidence of Fundoscopy grade 2 hypertensive or diabetic retinopathy
	Serum creatinine &gt; 1.5 mg/dl  
	Overt Proteinuria 
	Pregnant or lactating mothers 
	Evidence / History of Heart Failure
	Systolic Blood Pressure above 180 mmHg and Diastolic Blood Pressure above 110 mmHg 
	Recent history of Cerebrovascular disease, myocardial infarction, unstable angina, new onset LBBB in the past 4 weeks
	Documented case of homozygous familial hypercholesterolemia
	Type I Diabetes Mellitus
	Use of concomitant medications (cyclosporine, systemic itraconazole or ketoconazole, erythromycin, or clarithromycin, glucocorticoids or verapamil) known to affect the lipid profile or with potency safety concernRecent ongoing inter current infection / hs CRP &gt; 10 mg/L
	Active liver disease or hepatic dysfunction (defined as alanine aminotransferase (ALT), aspartate aminotransferase, alkaline phosphate or bilirubin levels = 1.5 the upper limit of normal
	Diagnosed to have any other endocrinal or metabolic disease other than Type II DM that is known to influence serum lipids and lipoproteins
	Patients having history suggestive of myalgia / myositis / arthralgia
	Serious or unstable medical or psychological condition that could compromise the patients safety or successful trial participation
	History of alcohol consumption &gt; 2 drinks/day (30 ml) or 10 drinks per week</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>15/09/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>360</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>India</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ranbaxy Laboratories Ltd</primarysponsorname>
    <primarysponsoraddress>Plot-90, Sector-32, Gurgaon, Haryana</primarysponsoraddress>
    <primarysponsorcountry>India</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Ranbaxy Laboratories Ltd</fundingname>
      <fundingaddress>Plot-90, Sector-32, Gurgaon, Haryana</fundingaddress>
      <fundingcountry>India</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Dhanvantri Independant Ethics Committee</ethicname>
      <ethicaddress>A-53/1, SFS Flat, SAKET New Delhi</ethicaddress>
      <ethicapprovaldate>11/06/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>5/06/2007</ethicsubmitdate>
      <ethiccountry>India</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Santosh Jha</name>
      <address>Plot-90, Sector-32, Gurgaon, Haryana</address>
      <phone>919910034380</phone>
      <fax />
      <email>dr.santoshjha@ranbaxy.com</email>
      <country>India</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Santosh Jha</name>
      <address>Plot-90, Sector-32, Gurgaon, Haryana</address>
      <phone>919910034380</phone>
      <fax />
      <email>dr.santoshjha@ranbaxy.com</email>
      <country>India</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Santosh Jha</name>
      <address>Plot-90, Sector-32, Gurgaon, Haryana</address>
      <phone>919910034380</phone>
      <fax />
      <email>dr.santoshjha@ranbaxy.com</email>
      <country>India</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>